What are the adverse effects of mycophenolate mofetil (MMF)?

Adverse Effects of Mycophenolate Mofetil (MMF)

Mycophenolate mofetil causes gastrointestinal side effects (nausea, vomiting, diarrhea, abdominal pain) in 3-50% of patients, hematologic toxicity (anemia, leukopenia, thrombocytopenia), increased infection risk, and is absolutely contraindicated in pregnancy due to severe teratogenicity.

Critical Safety Concerns

Pregnancy and Teratogenicity

MMF is contraindicated in pregnancy and must be discontinued at least 6-12 weeks before conception planning begins 1. The drug causes severe cranial, facial, and cardiac abnormalities in neonates 2. The most recent 2024 AGA guidelines emphasize that MMF should not be administered during pregnancy under any circumstances 1.

For women of reproductive potential:

• Mandatory pregnancy testing immediately before starting MMF and 8-10 days later 3
• Two forms of effective contraception required during treatment and for 6 weeks after discontinuation 1, 4, 3
• MMF reduces oral contraceptive effectiveness, requiring additional barrier methods 3
• Male patients must use contraception during treatment and for 90 days after stopping 4

Gastrointestinal Toxicity

The most common adverse effects are gastrointestinal, occurring in 45% of patients 5. Specific manifestations include:

• Diarrhea: 31-51% of patients 3
• Nausea and vomiting: 23-29% 6, 3
• Abdominal pain and cramping: 25-63% 2, 3
• MMF-induced colitis: 9% of patients, can be severe and difficult to diagnose 7, 5
• Gastrointestinal bleeding requiring hospitalization: 3% in renal, 1.7% in cardiac, 5.4% in hepatic transplant patients 3
• Gastrointestinal perforation: rare but documented 3

The 2025 EASL guidelines note that MMF has a discontinuation rate of only 0-8% due to side effects, significantly better than azathioprine's 15-36.5% 8. In autoimmune hepatitis specifically, drug-induced complications range from 3-34% 2.

Hematologic Toxicity

Bone marrow suppression occurs with variable frequency:

• Leukopenia: 23-45% 2, 3
• Anemia: 26-53% 2, 3
• Thrombocytopenia: 24-42% 3
• Neutropenia: documented in transplant patients, may require G-CSF or drug discontinuation 9

The 2014 dermatology guidelines note these hematologic effects are rare in non-transplant populations 6.

Infectious Complications

MMF weakens immune function and increases infection risk 3:

• Opportunistic infections: 10% higher incidence in cardiac transplant patients versus azathioprine 3
• Viral infections: herpes simplex, herpes zoster, cytomegalovirus (CMV) tissue invasive disease 10, 3
• BK virus: can cause kidney graft failure 3
• Hepatitis B and C reactivation 3
• Progressive multifocal leukoencephalopathy (PML): rare brain infection that can be fatal 10, 3

Elderly patients (≥65 years) are at particularly increased risk for CMV tissue invasive disease, gastrointestinal hemorrhage, and pulmonary edema 3.

Less Common but Significant Adverse Effects

• Hepatotoxicity: elevated liver enzymes (16.5% in some populations) 10, 11
• Genitourinary symptoms: urgency, frequency, dysuria 6, 12
• Headache and fatigue: common but not dose-dependent 6
• Refractory ascites: rare, possibly related to endothelial dysfunction 13
• Dermatologic reactions: drug-induced dermatitis with fever and diffuse erythematous rash 14
• Pure red cell aplasia: rare association 10

Long-Term Risks

• Malignancy: theoretical increased risk of cutaneous malignancy and lymphoma, though difficult to quantify in multidrug regimens 6, 12
• Progressive multifocal leukoencephalopathy: small increased risk with prolonged use 10

Monitoring Requirements

Based on FDA labeling 3:

• Complete blood counts regularly
• Liver function tests
• Renal function monitoring
• Pregnancy testing for women of reproductive potential
• Close observation in patients with delayed graft function or severe renal impairment

Clinical Context

The side effect profile of MMF is similar to azathioprine, making substitution difficult in severely cytopenic patients 2. However, the 2025 British Society of Gastroenterology guidelines note that MMF is better tolerated than azathioprine overall, with response rates of 62-92% in azathioprine-intolerant patients 4.

The frequency of adverse events varies by indication and patient population, with transplant patients generally experiencing higher rates than those treated for autoimmune conditions alone. Most gastrointestinal symptoms resolve within 20 days of discontinuation 5, and enteric-coated formulations may reduce GI complaints 6.